Drugmaker startup Peptilogics Inc. is partnering with a California artificial intelligence outfit to shrink the “cost of curiosity” in discovering new therapies.

Cerebras Systems of Sunnyvale wants to use its machine learning heft to help South Side-based Peptilogics accelerate the creation of peptide therapeutics by replacing scientific guesswork with machine learning and analysis to come up with drug candidates. Traditionally, a new drug takes about 10 years to develop; with Cerebras as a partner, Peptilogics hopes to reduce that time to months or even days, said Nick Nystrom, senior vice president and head of computation and data.

“AI approaches help to search large spaces and see things that humans haven’t seen before,” Mr. Nystrom said. “For this target, we can engineer peptide therapeutics with a high degree of success.”

Andy Hock, vice president of product management at Cerebras, said the partnership will increase the speed of drug development by reducing the scientific guesswork.

Advertise with us

“Cerebras Systems can enable bigger, faster and easier ways for Peptilogics to achieve their mission of discovering peptide therapeutics in record time, allowing the team to explore more ideas and to reduce the cost of curiosity,” he said in a prepared statement.

Peptides essentially are small proteins that play critical roles in how the human body works. More than 700 naturally occurring peptides have been identified, including ones crucial in hormonal actions, growth factors and neurotransmitters.

At least 80 peptide drugs have reached market. Insulin is a drug built on a peptide platform; Lantus, a long-acting insulin and Sanofi’s second-best selling pharmaceutical product in 2020, had $2 billion in sales in 2018. The global market for peptides in 2018 was estimated at $25 billion, according to analysts.

Advantages of the peptide platform for new drugs include fewer side effects, increased tissue penetration and simpler molecular design than other drugs. One hurdle that can impede patient compliance with prescription therapy: Peptide therapeutics most often must be injected instead of taken orally.

“AI approaches help to search large spaces and see things that humans haven’t seen before,” Mr. Nystrom said. “For this target, we can engineer peptide therapeutics with a high degree of success.”

Advertise with us

The therapeutic peptide market is competitive with pharmaceutical giants Eli Lilly & Co., Amgen Inc. and Bristol-Myers Squibb Co. among the players.

Peptilogics’ first medication, dubbed PLG0206, has been designated an orphan drug by the Food and Drug Administration, which will speed regulatory approval. The drug, which is an irrigation solution, is a broad spectrum anti-infective that targets bacterial infections caused by prosthetic joint infections.

Preparations for Phase I-B clinical trials are underway and marketing of the product is expected by 2026, said Jonathan Steckbeck, Peptilogics founder and president.

“We’re using a computational approach in design,” he said “Our goal is to do it unconstrained so the peptide platform could address any disease process.”

Peptilogics, which employs 22 people, with plans to hire three more people by Labor Day, has raised about $44 million in investment capital in five rounds since the company started in 2013. Peptilogics does not yet generate revenue.

Advertise with us

Peptilogics is part of the Pittsburgh area’s nascent life sciences industry. LyGenesis Inc. has received FDA clearance to proceed with a Phase 2-A study of the safety, tolerance and efficacy of its cell therapy for end stage liver disease after securing $11 million in private financing of convertible notes.

BlueSphere Bio, an immunotherapy startup in South Oakland that spun out of UPMC Enterprises, recently received $105 million in a tranche Series B investment after a first tranche of $45 million. The company is preparing to test its personalized T-cell therapies to treat cancer and other diseases.

Neubase Therapeutics Inc., also with offices in South Oakland, raised $42.6 million in an oversubscribed public offering in the third quarter of the fiscal year ending June 30. The revenue gives the precision genetic medicine company funding for operating and capital expenditures through the first quarter of 2023.

Updated 6:20 p.m. August 18

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699